

## BIOCORP: 2023 financial calendar

Issoire (France), January 5<sup>th</sup>, 2023, 6:00 pm CET – BIOCORP (FR0012788065 – ALCOR / Eligible PEA-PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, presents its financial reporting schedule for 2023<sup>(1)</sup>.

Annonce	Date*
2022 full-year results	Thursday, April 6 <sup>th</sup> , 2023 Before the market opening
Annual shareholders meeting	Tuesday, May 16 <sup>th</sup> , 2023
2023 first-half results	Thursday, September 28 <sup>th</sup> , 2023 Before the market opening

<sup>&</sup>lt;sup>(1)</sup> This schedule is indicative and subject to change.

## **ABOUT BIOCORP**

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 80 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit www.biocorpsys.com.

## CONTACTS BIOCORP

Jacques Gardette Chairman of the Board investisseurs@biocorp.fr Éric Dessertenne Chief Executive Officer Sylvaine Dessard

Marketing & Communication Director

rp@biocorp.fr

+ 33 (0)6 88 69 72 85

## CONTACTS ULYSSE COMMUNICATION

Bruno Arabian <u>barabian@ulysse-communication.com</u> +33 (0)6 87 88 46 26 Margaux Puech <u>mpuech@ulysse-communication.com</u> +33 (0)7 86 16 01 09



